Laurus Labs Stock Update: Share Price Rallies 1.7% on Strong Q1 Results
Laurus Labs (LAURUSLABS) share price surges over 1.7% to ₹1,788.90, hitting fresh all-time highs on robust Q1 FY27 results and MSCI inclusion buzz.
Laurus Labs is witnessing a strong uptrend in Wednesday's intraday trade, with the stock currently trading at ₹1,788.90, marking a significant gain of +1.71% from its previous close of ₹1,758.90. The stock opened higher at ₹1,762.00 and has since ascended to an intraday high of ₹1,797.90, well above its low of ₹1,754.30. This upward momentum is accompanied by a robust surge in trading volume, with 1,178,701 shares already exchanged, indicating strong buyer interest. The current price action clearly signals a continuation of the positive sentiment surrounding the pharmaceutical major.
| LAURUSLABS – Stock Updates as of (10:11AM, 29 Jul 2026) | |||
LTP ₹1,788.90 | Open ₹1,762.00 | High ₹1,797.90 | Low ₹1,754.30 |
52W High ₹0.00 | 52W Low ₹0.00 | Volume 1,178,701 | % Chg +1.71% |
52-Week Context
Today's move propels Laurus Labs into uncharted territory, as the stock is now trading at a fresh all-time high, surpassing its recent 52-week high of ₹1,752.70 recorded just yesterday, July 28, 2026. This remarkable ascent places the stock considerably above its 52-week low of approximately ₹810.05. The sustained rally indicates strong investor confidence, pushing the stock well beyond key annual resistance levels and signaling a breakout from its previous trading ranges.
Latest Developments
The primary catalyst driving Laurus Labs' impressive surge appears to be the stellar financial performance reported for the first quarter of fiscal year 2027 (Q1 FY27). The company announced that its net profit more than doubled, soaring by 126% year-on-year, while revenue registered a healthy 29% year-on-year growth. This exceptional performance was largely attributed to robust growth in its Contract Development and Manufacturing Organisation (CDMO) business and its affordable medicines portfolio. The company also highlighted significant margin expansion and reaffirmed its capital expenditure plans, which have further bolstered investor sentiment.
Adding to the positive sentiment is the persistent buzz around Laurus Labs' potential inclusion in the MSCI India index rejig, anticipated in August 2026. This potential inclusion could trigger substantial passive inflows, further boosting the stock's liquidity and institutional ownership. The broader Indian pharmaceutical sector has also been performing well, benefiting from a defensive rotation by investors amidst global market uncertainties, with healthcare generally outperforming. This sector-wide tailwind, combined with Laurus Labs' strong fundamentals and strategic growth areas, is contributing significantly to the current upward trajectory. Brokerages have noted the company's strong performance, with many anticipating further upside.
Outlook
For the remainder of the session, traders will be closely watching if Laurus Labs can sustain these new high levels and build further momentum, with eyes on potential profit-booking after the significant rally. The volume surge suggests continued interest, and the stock's ability to consolidate above the ₹1,780 mark will be a key indicator for its short-term trend.
Disclaimer: The information provided in this article is based on news reports and is not intended as investment advice. Investing in stocks involves risk. LatestLY advises its readers to consult with a financial advisor before making any investment decisions.
(The above story first appeared on LatestLY on Jul 29, 2026 10:10 AM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).
